EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

By R. Pirker, J. R. Pereira, J. von Pawel, M. Krzakowski, R. Ramlau, Keunchil Park, F. de Marinis, W. Eberhardt, L. Paz-Ares, S. Störkel and 4 more. 2012

Subfields: Cancer Research, Oncology